Inspira Technologies公司近日签署关键意向书，拟收购一项前沿液体活检癌症诊断技术。该技术突破性在于通过非侵入性血液检测实现精准肿瘤筛查，有望显著提升早期癌症诊断效率。
与此同时，公司宣布完成1500万美元战略融资，本轮投后估值达到1.8亿美元。资金将专项用于技术整合及临床推进，标志着液态活检领域再添重要布局。此次交易涵盖技术转让与股权投资双重环节，预计将强化公司在精准医疗领域的技术壁垒。
Inspira Technologies公司近日签署关键意向书，拟收购一项前沿液体活检癌症诊断技术。该技术突破性在于通过非侵入性血液检测实现精准肿瘤筛查，有望显著提升早期癌症诊断效率。
与此同时，公司宣布完成1500万美元战略融资，本轮投后估值达到1.8亿美元。资金将专项用于技术整合及临床推进，标志着液态活检领域再添重要布局。此次交易涵盖技术转让与股权投资双重环节，预计将强化公司在精准医疗领域的技术壁垒。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.